Abstracts of the 2023 Annual Meeting of the ALEH
More infoDiabetes mellitus (DM) is a chronic metabolic disease characterized by elevated blood glucose levels. DM1 manifests itself through hyperglycemia, the main factor inducing numerous life-threatening complications and comorbidities. DM has high morbidity and mortality associated with cardiovascular diseases, nephropathy and dyslipidemias, which are correlated with the deterioration of liver function. Maresin-1 (MaR1), a specialized pro-resolving lipid mediators has recently been described. MaR1 has a positive role in various inflammation-related pathologies particularly, it has favorable effect on chronic liver disease. This study aims to evaluate the effect of MaR1 administration on liver and kidney tissues in a murine model of DM1. Our hypothesis is that treatment produces an improvement in liver and kidney morphology.
Materials and Methodsmale C57BL/6 mice where induced DM1 by Spreptozotocin injection (50mg/Kg) and MaR1 (4ng/g) diary for 4 weeks. Liver and Kidneys were processed for H&E and Masson´s Trichrome stain and morphological analyzed. An immunohistochemical study was also carried out with the use of antibodies to fibronectin and -SMA. The data was evaluated by Image J and Prism 9 software's.
ResultsBoth in liver and kidney, the MaR1 animal group recovers the cito-architecture and decreased the score of fibrosis in comparison with DM group, resembling the control group. In liver tissue a decrease of lipids deposit was observed in the MaR1, concomitant with the architecture improvement.
ConclusionsMar1 at 4 ng/g generates a positive response in the liver and kidney morphology, depleting the tissue damage observed in a DM1 murine model. Deeper analysis should carry on for to enlarge this results and assay Mar1 as a potential therapeutic activity against one of the most prevalent diseases in the world, the DM.
